Open AccessUse of MSCs and MSC-Educated Macrophages to Mitigate Hematopoietic Acute Radiation Syndrome
Author(s) -
Raghavan Chinnadurai,
Matthew H. Forsberg,
John A. Kink,
Peiman Hematti,
Christian M. Capitini
Publication year - 2020
Publication title -
current stem cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.865
H-Index - 17
ISSN - 2198-7866
DOI - 10.1007/s40778-020-00176-0
Subject(s) - mesenchymal stem cell , medicine , cell therapy , haematopoiesis , stem cell , immune system , clinical trial , hematopoietic stem cell , exosome , stem cell therapy , cancer research , immunology , microvesicles , pathology , biology , microrna , biochemistry , gene , genetics
Innovative and minimally toxic treatment approaches are sorely needed for the prevention and treatment of hematopoietic acute radiation syndrome (H-ARS). Cell therapies have been increasingly studied for their potential use as countermeasures for accidental and intentional ionizing radiation exposures which can lead to fatal ARS. Mesenchymal stem/stromal cells (MSCs) are a cell therapy that have shown promising results in preclinical studies of ARS, and are being developed in clinical trials specifically for H-ARS. MSCs, MSC-educated macrophages (MEMs) and MSC-exosome educated macrophages (EEMs) all have the potential to be used as adoptive cell therapies for H-ARS. Here we review how MSCs have been reported to mitigate inflammation from radiation injury while also stimulating hematopoiesis during ARS.